What happened: A new UK-US agreement exempts British drug exports from US tariffs and relaxes NHS pricing rules to improve patient access to some treatments. Critics warn the deal could reduce NHS funding by billions.
Why it matters:
- UK pharmaceutical companies benefit from tariff-free exports to the US market.
- The NHS may face higher costs, potentially affecting healthcare budgets and services.
MNN Take: The deal aims to support UK drug exports and expand patient access to medicines, but it also raises concerns about increased NHS spending and financial pressures.
Sources: Guardian UK